PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign ...

Procept BioRobotics today announced the international rollout of its next-generation Hydros robotic system for Aquablation therapy.

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on PRCT. PROCEPT ...

Analysts expect PROCEPT BioRobotics to report an earnings per share (EPS) of $-0.32. PROCEPT BioRobotics bulls will hope to ...

Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $47 but keeps a Buy rating on the shares. The company’s Q4 missed estimates, though its Analyst Day laid out a case for ...

Fintel reports that on March 6, 2026, Baird initiated coverage of PROCEPT BioRobotics (NasdaqGM:PRCT) with a Neutral recommendation. Analyst Price Forecast Suggests 122.20% Upside As of February 25, ...

PROCEPT BioRobotics PRCT is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

Jefferies initiated coverage of Procept BioRobotics (PRCT) with a Hold rating and $95 price target The firm’s checks suggest the Hydros system launch could catalyze a replacement cycle among systems ...

PROCEPT BioRobotics ( (PRCT)) has shared an update. On March 5, 2026, PROCEPT BioRobotics expanded its board of directors from eight to nine members and appointed former Shockwave Medical Chief ...

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing ...

Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure ...